Filana Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Filana Therapeutics, Inc. (FLNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-07
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was -1.38M shares, a 270.25% decline year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 1.57M shares, a 45.09% increase year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 1.47M shares, a 672.11% increase year-over-year.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.66M shares, a 20.55% decline from fiscal 2024.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.08M shares, a 79.26% increase from fiscal 2023.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.16M shares, a 1017.31% increase from fiscal 2022.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 104.00K shares, a 4.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | -1.38M shares derived: sum of 2 quarters · filed 2026-05-07 | 188.00K shares derived: sum of 3 quarters · filed 2026-05-07 | 1.66M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | -1.38M shares derived: 10-K 12 month − 3 quarters · filed 2026-03-12 | 188.00K shares derived: sum of 2 quarters · filed 2026-03-12 | 1.66M shares derived: sum of 3 quarters · filed 2026-03-12 | 1.66M shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 1.57M shares 10-Q · filed 2025-11-12 | 3.03M shares derived: sum of 2 quarters · filed 2025-11-12 | 3.03M shares derived: sum of 3 quarters · filed 2025-11-12 | 3.84M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 1.47M shares 10-Q · filed 2025-08-14 | 1.47M shares derived: sum of 2 quarters · filed 2025-08-14 | 2.28M shares derived: sum of 3 quarters · filed 2025-08-14 | 3.36M shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 810.00K shares derived: sum of 2 quarters · filed 2025-05-08 | 1.89M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.08M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 810.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 1.89M shares derived: sum of 2 quarters · filed 2025-03-03 | 2.08M shares derived: sum of 3 quarters · filed 2025-03-03 | 2.08M shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 1.08M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 1.27M shares derived: sum of 2 quarters · filed 2024-11-07 | 1.27M shares 10-Q · filed 2024-11-07 | 2.30M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 190.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 193.00K shares 10-Q · filed 2024-08-08 | 1.22M shares derived: sum of 3 quarters · filed 2024-08-08 | |
| 2024-03-31 | 3.00K shares 10-Q · filed 2024-05-10 | 1.03M shares derived: sum of 2 quarters · filed 2024-05-10 | ||
| 2023-12-31 | 1.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 1.16M shares 10-K · filed 2024-02-28 | ||
| 2023-09-30 | 132.00K shares 10-Q · filed 2023-11-07 | |||
| 2022-12-31 | 104.00K shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 100.00K shares 10-K · filed 2022-03-01 | |||
| 2020-12-31 | 60.00K shares 10-K · filed 2021-03-23 | |||
| 2019-12-31 | 425.00K shares 10-K · filed 2020-03-26 | |||
| 2018-12-31 | 297.50K shares 10-K · filed 2019-03-29 | |||
| 2017-12-31 | 1.03M shares 10-K · filed 2018-02-06 | |||
| 2016-12-31 | 355.00K shares 10-K · filed 2017-03-07 | |||
| 2015-12-31 | 1.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | 1.61M shares derived: sum of 2 quarters · filed 2016-03-03 | 2.21M shares 10-K · filed 2016-03-03 | |
| 2015-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | 595.00K shares 10-Q · filed 2015-11-09 | ||
| 2015-06-30 | 595.00K shares 10-Q · filed 2015-07-23 | |||
| 2014-12-31 | 3.52M shares 10-K · filed 2015-02-18 | |||
| 2013-12-31 | 1.87M shares 10-K · filed 2014-02-05 | |||
| 2012-12-31 | 1.08M shares 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |